May 1, 2026

Novo Ozempic Pill US Launch and WW + GoodRx Channel Expansion, Lilly Stock Jumps 6%, Foundayo Week 3 IQVIA Hits 5,612, Utah PapB Cyclizes GLP-1-Like Peptides

Novo unveils Ozempic pill for US adults with T2D plus WW Med+ and GoodRx channels, Lilly stock jumps 6.11% post-Q1, Foundayo Week 3 hits 5,612 scripts, Utah's PapB enzyme cyclizes GLP-1-like peptides.

10 stories · Covering industry, clinical-trials, regulatory, research

Editor's Note

The Ozempic-pill ecosystem launched today: Novo Nordisk announced May 4 US availability of oral semaglutide tablets at 1.5/4/9 mg through more than 70,000 pharmacies, with WeightWatchers' Med+ adding the medication to its clinically-supervised channel and GoodRx publishing self-pay pricing tiers ($149/$199/$299) the same morning — all positioning Ozempic Pill as the first FDA-approved oral peptide GLP-1 cleared for cardiovascular risk reduction in adults with type 2 diabetes. Eli Lilly's Q1 2026 print drove a 6.11% share-price gain on May 1 as analysts re-priced the Mounjaro/Zepbound trajectory and the raised $82–85B revenue guidance, even as IQVIA's Week 3 Foundayo tracker showed 5,612 prescriptions — climbing but still well behind the oral Wegovy launch curve. Beyond GLP-1s, the FDA's PCAC public-comment docket FDA-2025-N-6895 opened ahead of the July 23–24 review of seven peptides for the 503A bulks list, ResearchAndMarkets released a peptide and oligonucleotide CDMO outlook projecting the segment past $4 billion by 2030, the University of Utah's PapB radical-SAM enzyme paper landed in ACS Bio & Med Chem Au showing one-step cyclization of GLP-1-like peptides via a thioether bond, BriaCell announced six ASCO 2026 presentations on Bria-IMT in metastatic breast cancer, and Lilly's $2.25B Profluent recombinase pact extended its diversification beyond peptide therapeutics into AI-designed genetic medicine.

Industry

Novo Nordisk Ozempic Pill (Oral Semaglutide) Lands in US Pharmacies May 4 — First FDA-Approved Oral Peptide GLP-1 with CV Risk Reduction

Novo Nordisk announced May 1 that Ozempic (semaglutide) tablets at 1.5 mg, 4 mg, and 9 mg will be available across 70,000+ U.S. pharmacies starting Monday, May 4, for adults with type 2 diabetes. The product is the only FDA-approved oral peptide GLP-1 medication cleared for both primary and secondary cardiovascular risk reduction in adults with T2D, manufactured end-to-end in the United States. Insured patients can access the pill for as little as $25 for up to a 3-month supply; self-pay patients face $149–$299/month depending on dose strength.

#novo-nordisk #ozempic-pill #oral-semaglutide #glp-1 #type-2-diabetes #cardiovascular

Industry

WeightWatchers Med+ Adds Ozempic Pill Access for Type 2 Diabetes Members

WeightWatchers announced May 1 that its Med+ platform and affiliated medical groups will begin offering Ozempic pill (oral semaglutide) for clinically eligible members with type 2 diabetes. Many eligible members can access the medication for as low as $25/month with pharmacy benefits. The expansion adds a once-daily oral GLP-1 alongside the existing Med+ portfolio of clinically supervised weight-management and metabolic-health treatments, giving WW a foothold in T2D care to complement its weight-loss positioning.

#weightwatchers #ww-med-plus #ozempic-pill #type-2-diabetes #telehealth

Industry

GoodRx Publishes Self-Pay Pricing for Ozempic Pill: $149 / $199 / $299 per Month by Strength

GoodRx announced May 1 that it has added self-pay access for the Ozempic pill, offering eligible patients with type 2 diabetes the medication at $149/month for the 1.5 mg dose, $199/month for 4 mg, and $299/month for 9 mg at participating pharmacies nationwide. The collaboration extends GoodRx's existing work across Novo Nordisk's full semaglutide portfolio, letting cash-paying patients bypass insurance complexity at the counter. The launch closes a transparency gap that has dogged consumer access to oral GLP-1 therapy.

#goodrx #novo-nordisk #ozempic-pill #self-pay #cash-price #glp-1

Industry

Lilly Stock Rises 6.11% on May 1 Following Q1 Beat and $82–85B Guidance Raise

Eli Lilly shares climbed 6.11% on May 1 as the market digested the company's Q1 2026 print: $19.8B in revenue (+56% YoY), Mounjaro at $8.66B globally (+125%), Zepbound at $4.16B in U.S. sales (+80%), and reported EPS of $8.26 versus the $6.97 consensus. Multiple sell-side analysts revised price targets higher and reiterated or upgraded ratings, citing the strength of the cardiometabolic franchise and the $2 billion guidance raise to $82–85B. The reaction crystallized Lilly's positioning as the GLP-1 leader heading into Novo's May 6 Q1 print.

#eli-lilly #lly-stock #q1-earnings-reaction #mounjaro #zepbound #analyst-upgrades

Clinical Trials

Foundayo Week 3 IQVIA Tracker: 5,612 Prescriptions, Up 51% Week-Over-Week but Still Trailing Oral Wegovy's Launch Curve

Fierce Pharma's Oral GLP-1 Tracker reported May 1 that Eli Lilly's Foundayo (orforglipron) reached 5,612 prescriptions in the week ending April 24 — its third full commercial week — up roughly 51% from Week 2's 3,707 scripts but still behind the Wegovy pill's comparable third-week run. RBC and other analysts continue to caution that 8–12 weeks of data are needed to read commercial trajectory through pharmacy-fill noise. On the Q1 earnings call, Lilly USA's Ilya Yuffa said roughly 20,000 patients are now on the drug for obesity or overweight, calling the early launch 'encouraging.'

#foundayo #orforglipron #eli-lilly #iqvia #launch-tracker #oral-glp-1

Industry

Eli Lilly Signs $2.25B Pact with Profluent for AI-Designed Site-Specific Recombinases in Genetic Medicine

Profluent, the Bezos-backed AI biotech, announced April 28 a multi-program research collaboration with Eli Lilly worth up to $2.25B in development and commercial milestones plus tiered royalties. Profluent will use its AI platform to design custom recombinases that integrate or modify large stretches of DNA at precise genomic loci, with the goal of generating site-specific gene-editing therapies for diseases of severe unmet need. The deal extends Lilly's diversification beyond peptide therapeutics, following a $1.12B Seamless Therapeutics recombinase deal in January 2026 and the closed Kelonia Therapeutics, Centessa, Orna, and Ajax acquisitions earlier in the quarter.

#eli-lilly #profluent #ai-drug-discovery #recombinase #gene-editing #lilly-pipeline

Industry

Peptide & Oligonucleotide CDMO Market Forecast: $2.7B in 2026 Climbing Past $4B by 2030 on GLP-1 Demand

ResearchAndMarkets released a Peptide and Oligonucleotide CDMO Market Research Report on April 30 forecasting the global market expanding from $2.42B in 2025 to $2.7B in 2026 (11.9% CAGR), reaching $4.03B by 2030. The report names Bachem, PolyPeptide, CordenPharma, and AmbioPharm as the dominant capacity holders capturing roughly 55–60% of global revenue. Demand for GLP-1 receptor agonists and siRNA drugs is outpacing GMP suite availability, giving CDMOs unusual pricing power in multi-year capacity contracts. The report frames manufacturing capacity as the binding constraint on the next wave of peptide therapeutics.

#peptide-cdmo #oligonucleotide-cdmo #bachem #polypeptide #manufacturing-capacity #market-forecast

Regulatory

FDA Pharmacy Compounding Advisory Committee Public Docket FDA-2025-N-6895 Open for Comments Ahead of July 23–24 Peptide Review

The FDA's PCAC public docket FDA-2025-N-6895 is now accepting written comments on the proposed addition of seven peptides to the Section 503A bulk drug substances list ahead of the July 23–24 advisory committee meeting at White Oak. Day 1 will cover BPC-157, KPV, TB-500, and MOTs-C; Day 2 will cover Emideltide (DSIP), Semax, and Epitalon. Comments received by July 9 are guaranteed to be presented to the committee, and the docket closes July 22. The window gives compounders, prescribers, and patient advocates roughly twelve weeks to formally submit clinical evidence, pharmacovigilance data, and access arguments.

#fda #pcac #503a-bulks-list #bpc-157 #kpv #tb-500 #epitalon #semax #public-comment

Research

University of Utah PapB Enzyme Performs One-Step Thioether Cyclization of GLP-1-Like Peptides — Cleaner Path to Macrocyclic Drug Candidates

ScienceDaily on April 27 highlighted a University of Utah Department of Chemistry team's discovery — published in ACS Bio & Med Chem Au — that the radical-SAM enzyme PapB can macrocyclize GLP-1-like peptides in one step by forming a thioether bond between a cysteine thiol and the C-terminal carboxylate, even when the C-terminal residue is D-configured, β-amino-acid-derived, or N-methylated. The chemistry compresses what is normally a multi-step late-stage cyclization into a single enzymatic reaction, materially reducing the cost and complexity of producing oral-bioavailable peptide drugs. The work positions PapB as a platform tool for next-generation incretin and macrocyclic peptide programs.

#university-of-utah #papb #radical-sam #thioether-cyclization #macrocyclic-peptides #glp-1 #peptide-chemistry

Clinical Trials

BriaCell Announces Six Bria-IMT Peptide Immunotherapy Presentations at ASCO 2026 Including 12- and 24-Month Survival Update

BriaCell announced April 27 that its Bria-IMT cell-based peptide immunotherapy will be featured in three poster presentations and three publication-only abstracts at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago). Highlights include 12- and 24-month overall survival data with Bria-IMT plus checkpoint inhibition in advanced metastatic breast cancer, an updated quality-of-life and tolerability analysis, and a randomized Bria-ABC Phase 3 blood-biomarker progression-free survival readout. Three publication-only abstracts cover the second-generation BC1 platform, multi-analyte liquid biopsy stratification, and PD-L1 monitoring in circulating cancer-associated cells.

#briacell #bria-imt #peptide-immunotherapy #metastatic-breast-cancer #asco-2026 #checkpoint-inhibitor